News

Deal Announcements

Esperas Pharma Closes Series A Financing

Thursday, April 16, 2015 5:46:00 AM PDT | VentureDeal
Montréal, Canada  --  Esperas Pharma (no website) has received an undisclosed amount of first round venture capital investment.

Esperas is a special-purpose company created to develop a single compound for women with triple-negative breast cancer to the point of proof of concept.

Investors in the financing were TVM Capital and Fonds de Solidarite FTQ.

The company did not disclose how the funding proceeds would be used.

Esperas is led by CEO Caroline Fortier.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1